Join Now

Category Archives: BioUtah News

Merit Medical’s WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment

By Natalie Themm | Published August 3, 2023

SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis […]

| Tagged | Comments Off on Merit Medical’s WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment

Alucent Biomedical Wins FDA Approval for U.S. Clinical Study

By Natalie Themm | Published August 3, 2023

U.S. FDA Grants an Investigational Device Exemption for Trial Evaluating Novel AlucentNVS Technology

| Tagged | Comments Off on Alucent Biomedical Wins FDA Approval for U.S. Clinical Study

Quansys Biosciences and The Michael J. Fox Foundation Partner to Accelerate Parkinson’s Disease Research

By Natalie Themm | Published August 3, 2023

Quansys Biosciences and The Michael J. Fox Foundation, announced a strategic partnership to accelerate research into PD.

| Tagged | Comments Off on Quansys Biosciences and The Michael J. Fox Foundation Partner to Accelerate Parkinson’s Disease Research

Government Price Setting Would Lead to Lost Therapies, Innovation and Jobs in Utah

By admin | Published August 2, 2023

New Study Details Proposed Federal Government-Mandated Drug Pricing Policies Senate SMART Prices Act Will Cost More Than 235 Fewer FDA Approvals Up To 23,000 Lost Jobs in Utah in Coming Decade SALT LAKE CITY, July 27, 2023 – Proposed expansions of federal government-mandated drug pricing policies present serious consequences for the development of and investment in […]

| Comments Off on Government Price Setting Would Lead to Lost Therapies, Innovation and Jobs in Utah

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

By admin | Published July 27, 2023

Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships.SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding […]

| Comments Off on Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

DEVICE FOR TREATING CHALLENGING BONE FRACTURES CLEARED BY FDA

By admin | Published July 27, 2023

A new system for fixing bone fractures, called the Bone Bolt System, has been approved for market by the U.S. Food and Drug Administration (FDA), the University of Utah Orthopaedic Innovation Center (OIC), Department of Orthopaedics and Spencer Fox Eccles School of Medicine announced on July 20, 2023. “This achievement demonstrates the commitment by the […]

| Comments Off on DEVICE FOR TREATING CHALLENGING BONE FRACTURES CLEARED BY FDA

Owlet Appoints Executive Jonathan Harris as New Company President and Chief Revenue Officer

By admin | Published July 27, 2023

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, today announces the appointment of executive Jonathan Harris as its new President and Chief Revenue Officer. Harris joins Owlet at a pivotal time in its business – one month after receiving clearance from the U.S. Food and Drug […]

| Comments Off on Owlet Appoints Executive Jonathan Harris as New Company President and Chief Revenue Officer

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

By Natalie Themm | Published July 27, 2023

RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers. This comprehensive model is expected to identify more patients that could benefit from a change in their breast care.

| Tagged | Comments Off on Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System

By Natalie Themm | Published July 27, 2023

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring, auto-identification, dose error reduction software and EMR interoperability BD Alaris™ Infusion System’s unique “One System” platform securely connects all patient modules to provide care teams […]

| Tagged | Comments Off on BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

By Natalie Themm | Published July 27, 2023

Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally

| Tagged | Comments Off on Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Owlet Appoints Healthcare Executive Melissa Gonzales to Board of Directors

By admin | Published July 20, 2023

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, is pleased to announce the addition of Melissa Gonzales to the Company’s Board of Directors. Gonzales brings more than 20 years of consumer and provider healthcare experience to Owlet, further advancing the Company as a leader in infant monitoring solutions. […]

| Comments Off on Owlet Appoints Healthcare Executive Melissa Gonzales to Board of Directors

Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program

By admin | Published July 20, 2023

The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform SALT LAKE CITY, July 13, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development […]

| Comments Off on Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program

A Special Thanks To Our Legacy and Platinum Elite Members